KAS
DYN icon

Kemnay Advisory Services’s Dyne Therapeutics DYN Stock Holding History

Kemnay Advisory Services’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.9K Buy
1,303
+117
+10% +$2.17K ﹤0.01% 520
2026
Q1 		$21.5K Buy
+1,186
New +$20.5K ﹤0.01% 646

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Kemnay Advisory Services's DYN Position: Q2 2026 in Review

Kemnay Advisory Services increased its Dyne Therapeutics (DYN) stake by 9.9% in Q2 2026, buying an estimated $2.17K and bringing the position to 1,303 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #520.

Kemnay Advisory Services first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Kemnay Advisory Services held 1,303 shares of Dyne Therapeutics worth $28.9K as of Q2 2026.
  • Kemnay Advisory Services bought 117 Dyne Therapeutics shares in Q2 2026, an estimated $2.17K.
  • Dyne Therapeutics made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #520 holding.
  • Kemnay Advisory Services first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.